Oral Thin Film Drugs Market Size, Share, Growth, Trends, and Global Industry Analysis: By Product (Fast Dissolving Buccal Film, Sublingual Film), By Application (Anti-Emetic, Opioid Dependence, Schizophrenia, Anti-Migraine, Dietary Supplements, Mouth Freshener, Sedative & Hypnotic, Anti-Flatulent, Smoking Cessation, Vitamin D3 Supplements, Anti-Allergic/Nasal Decongestion, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Drug Stores, Others) and Region

Oral Thin Film Drugs Market size was valued at US$ 2,892.7 million in 2023 and is projected to grow at a CAGR of 9.7% from 2024 to 2030. The global oral thin films market provides a suitable and patient-friendly alternative to conventional oral dosage forms like tablets and capsules. Oral thin films are a thin films used for oral administration of drugs to people who face difficulty in swallowing. The active substances from this oral thin films directly enters into the system through the oral mucosa. These are made up of water-soluble polymers to increase the drug solubility. Oral thin films have a wide range of advantages such as ease of administration, accurate dosage, rapid disintegration, and potentially improved patient compliance. They are used to deliver a variety of pharmaceutical compounds, including prescription drugs, over-the-counter medications, and nutraceuticals. The market is facing robust growth due to the increasing burden of target diseases, technological advancements in drug discovery and development, strategic alliances between novel technology owners and large pharmaceutical companies, less bio-availability of solid drugs, and inaccurate dosage by liquid formulations, and growing geriatric population all over the world. increasing demand for effective drug delivery systems worldwide is estimated to provide major growth opportunities for players in the oral thin films market. Moreover, increasing demand for oral thin films worldwide owing to rising awareness among people is projected to enhance the growth of the market. However, factors such as limitations related to oral films and availability of substitute drugs are likely to obstruct the growth of the global oral thin films market.

 Recent Market Developments:

• In March 2021, Aquestive Therapeutics Inc. illustrated a widespread analysis of the science, clinical results, and development strategy of its PharmFilm oral sublingual film for administering epinephrine. This product is advertised to treat allergic reactions including anaphylaxis effectively.
• In August 2020, The ZIM laboratories Ltd and Hypera Pharma Group made an agreement to market Vitamin D3 in novel oral thin film.